Tomas Kiselak is Director & 10% Owner at Dianthus Therapeutics, Inc. /DE/ (DNTH). They have made 3 open-market trades across 1 company since 2023, most recently 2025-09-17.
CIK 0001830177
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
3 open-market purchases totalling $1.3M since 2023, never a sale. Too few scored purchases to measure a record yet.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.